Cargando…

Prognostic value of des-γ-carboxyprothrombin in patients with AFP-negative HCC treated with TACE

In patients with AFP-negative hepatocellular carcinoma (HCC), des-γ-carboxyprothrombin (DCP) is an important prognostic indicator for the preoperative assessment of transarterial chemoembolization (TACE). However, the association between the serum DCP levels and the degree of progression and prognos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Hanyao, Yang, Wei, Zhou, Weizhong, Zhou, Chungao, Liu, Sheng, Shi, Haibin, Tian, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827467/ https://www.ncbi.nlm.nih.gov/pubmed/36644150 http://dx.doi.org/10.3892/ol.2022.13655

Ejemplares similares

Diagnostic Value of hTERT mRNA and in Combination With AFP, AFP-L3%, Des-γ-carboxyprothrombin for Screening of Hepatocellular Carcinoma in Liver Cirrhosis Patients HBV or HCV-Related
por: Nguyen, Hoang Bac, et al.
Publicado: (2022)

Prognostic Values of Alpha-Fetoprotein and Des-Gamma-Carboxyprothrombin in Hepatocellular Carcinoma in China: An Analysis of 4792 Patients
por: Pan, Yang-Xun, et al.
Publicado: (2021)

Des-γ-Carboxyprothrombin Plasma Level in Diagnosis of Hepatocellular Carcinoma in a Chinese Population Undergoing Surgery
por: Feng, Xiaobin, et al.
Publicado: (2016)

Des-γ-Carboxyprothrombin (DCP) and NX-DCP Expressions and Their Relationship with Clinicopathological Features in Hepatocellular Carcinoma
por: Sumi, Akiko, et al.
Publicado: (2015)

Effect of sorafenib on des-γ-carboxyprothrombin secretion by a human hepatocellular carcinoma cell line
por: Ogasawara, Sachiko, et al.
Publicado: (2017)

Inclusive Quantification Assay of Serum Des‐γ‐Carboxyprothrombin Proteoforms for Hepatocellular Carcinoma Surveillance by Targeted Mass Spectrometry
por: Lee, Jihyeon, et al.
Publicado: (2021)

Investigation of Potential Molecular Biomarkers for Diagnosis and Prognosis of AFP-Negative HCC
por: Liu, Zijing, et al.
Publicado: (2021)

Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis
por: Yao, Man, et al.
Publicado: (2022)

Evaluation of D-TACE combined with endovascular brachytherapy for HCC with MPVTT
por: Huang, Wei, et al.
Publicado: (2022)

Des-gamma-carboxyprothrombin is a favorable biomarker for the early diagnosis of alfa-fetoprotein-negative hepatitis B virus-related hepatocellular carcinoma
por: Liu, Zhaobo, et al.
Publicado: (2020)

FAIL-T (AFP, AST, tumor sIze, ALT, and Tumor number): a model to predict intermediate-stage HCC patients who are not good candidates for TACE
por: Kaewdech, Apichat, et al.
Publicado: (2023)

Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study
por: Lucatelli, Pierleone, et al.
Publicado: (2021)

Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS
por: Fan, Wenzhe, et al.
Publicado: (2021)

Changing TACTICS in intermediate HCC: TACE plus sorafenib
por: Radu, Pompilia, et al.
Publicado: (2020)

Combination of dual serum fluorescence, AFP and hepatic function tests is valuable to identify HCC in AFP-elevated liver diseases
por: Wang, Ting, et al.
Publicado: (2017)

Correction to: Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study
por: Lucatelli, Pierleone, et al.
Publicado: (2021)

Utility of serum des-gamma-carboxyprothrombin in the diagnosis of hepatocellular carcinoma among Nigerians, a case–control study
por: Ette, Akpakip I., et al.
Publicado: (2015)

Combining des-gamma-carboxyprothrombin and alpha-fetoprotein for hepatocellular carcinoma diagnosing: an update meta-analysis and validation study
por: Chen, Huaping, et al.
Publicado: (2017)

AFP ratio predicts HCC recurrence after liver transplantation
por: Koch, Christine, et al.
Publicado: (2020)

CT-radiomics and clinical risk scores for response and overall survival prognostication in TACE HCC patients
por: Bernatz, Simon, et al.
Publicado: (2023)

COCH predicts survival and adjuvant TACE response in patients with HCC
por: Wang, Chen, et al.
Publicado: (2021)

Tumor SOCS3 methylation status predicts the treatment response to TACE and prognosis in HCC patients
por: Jiang, Bei-Ge, et al.
Publicado: (2017)

Diagnostic value of alpha-fetoprotein, Lens culinaris agglutinin-reactive alpha-fetoprotein, and des-gamma-carboxyprothrombin in hepatitis B virus-related hepatocellular carcinoma
por: Song, Ting, et al.
Publicado: (2019)

Preoperatively predicting early response of HCC to TACE using clinical indicators and MRI features
por: Li, Zhi-Wei, et al.
Publicado: (2022)

Upregulation of Serum Sphingosine (d18:1)-1-P Potentially Contributes to Distinguish HCC Including AFP-Negative HCC From Cirrhosis
por: Jiang, Yingying, et al.
Publicado: (2020)

The effect of lipiodol deposition in HCC after TACE on the necrosis range of PMCT
por: Sun, HongLiang, et al.
Publicado: (2017)

Hybrid Modelling of Transarterial Chemoembolisation Therapies (TACE) for Hepatocellular Carcinoma (HCC)
por: Perfahl, H., et al.
Publicado: (2020)

CXCL1 and CXCL6 Are Potential Predictors for HCC Response to TACE
por: Kinzler, Maximilian N., et al.
Publicado: (2023)

Inflammation-Related Marker NrLR Predicts Prognosis in AFP-Negative HCC Patients After Curative Resection
por: Wu, Qionglan, et al.
Publicado: (2023)

Efficacy and safety of TACE combined with lenvatinib and PD‐1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study
por: Wang, Wei‐Jun, et al.
Publicado: (2023)

Transcatheter arterial chemoembolization (TACE) combined with γ-knife compared to TACE or γ-knife alone for hepatocellular carcinoma
por: Cai, Yeyu, et al.
Publicado: (2018)

Duration of response after DEB-TACE compared to lipiodol-TACE in HCC-naïve patients: a propensity score matching analysis
por: Bargellini, Irene, et al.
Publicado: (2021)

Clinical values of AFP, GPC3 mRNA in peripheral blood for prediction of hepatocellular carcinoma recurrence following OLT: AFP, GPC3 mRNA for prediction of HCC
por: Wang, Yuliang, et al.
Publicado: (2011)

Novel Value of Preoperative Gamma-Glutamyltransferase Levels in the Prognosis of AFP-Negative Hepatocellular Carcinoma
por: Lu, Liang-He, et al.
Publicado: (2020)

Comparative analysis of tumor-associated vascular changes following TACE alone or in combination with sorafenib treatment in HCC: A retrospective study
por: Chen, Ligang, et al.
Publicado: (2018)

Published trials of TACE for HCC are often not registered and subject to outcome reporting bias
por: Grégory, Jules, et al.
Publicado: (2020)

The Feasibility of TACE Combined with TKIs Plus PD-1 Antibody for Advanced HCC
por: Sun, Tao, et al.
Publicado: (2023)

The diagnostic value of PIVKA‐II, AFP, AFP‐L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma
por: Qi, Famei, et al.
Publicado: (2019)

Efficacy and Safety of Combined Ethanol-Lipiodol Mixture and Drug-Eluting Bead TACE for Large HCC
por: Chuang, Yi-Hsuan, et al.
Publicado: (2023)

Development and Validation of a Prognostic Nomogram in AFP-negative hepatocellular carcinoma
por: Wang, Xueping, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pjlckh3pdin0kbj94ldp1oirnj